CNMAu8

Phase 2Small molecule

CClene Nanomedicine

CNMAu8 is one of 40 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisActive, not recruiting

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

220 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Tivicay

GSK

Phase 3

2 2

Radicava

Shionogi

Phase 3

2 3

Simdax

Orion Corporation, Orion Pharma

Phase 3

1 4

Robitussin

Ultomiris

Lithobid

SSolvay Pharmaceuticals

Phase 3

3 7

Minocin

TTriax

Phase 3

2 8

Sodium Valproate

AstraZeneca

Phase 3

1 9

BOTULINUM TOXIN TYPE B

Eisai

Phase 3

1 10

Colcrys

Alnylam Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Amyotrophic Lateral Sclerosis

NCT05299658

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis1 trial

An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

Active, not recruiting·CClene Nanomedicine·Phase 2·NCT05299658·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CNMAu8. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CNMAu8 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CNMAu8. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clene Nanomedicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CClene Nanomedicine

CNMAu8

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Amyotrophic Lateral Sclerosis1 trial

References

Drug Info

Quick Facts

Related News